← Back to Search

Educational Video for Vaccine Hesitancy in Sickle Cell Disease

N/A
Recruiting
Led By John Strouse, MD, PhD
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of sickle cell disease
Be older than 18 years old
Must not have
Unable to read or understand spoken English to complete the survey
Timeline
Screening 3 weeks
Treatment Varies
Follow Up before and after watching video
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a COVID-19 info video to reduce vaccine hesitancy in adults w/ sickle cell. Participants watch a video & answer surveys before & after to measure impact.

Who is the study for?
This trial is for adults with sickle cell disease who are hesitant about getting the COVID-19 vaccine. They must be able to read and understand English as they will need to complete a survey.
What is being tested?
The study tests whether a specially made video with COVID-19 vaccination information can help reduce vaccine hesitancy in adults with sickle cell disease. Participants watch the video and then answer survey questions.
What are the potential side effects?
Since this trial involves watching an informational video rather than taking medication, there are no direct medical side effects associated with participating in this study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with sickle cell disease.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot read or understand English well enough to complete a survey.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~before and after watching video
This trial's timeline: 3 weeks for screening, Varies for treatment, and before and after watching video for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Vaccine hesitancy

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Adults With Sickle Cell DiseaseExperimental Treatment1 Intervention
Age 18 years or older

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,451 Previous Clinical Trials
2,971,509 Total Patients Enrolled
2 Trials studying Vaccine Hesitancy
1,777 Patients Enrolled for Vaccine Hesitancy
American Society of HematologyOTHER
12 Previous Clinical Trials
20,741 Total Patients Enrolled
John Strouse, MD, PhDPrincipal InvestigatorDuke University

Media Library

Adults With Sickle Cell Disease Clinical Trial Eligibility Overview. Trial Name: NCT05998824 — N/A
Vaccine Hesitancy Research Study Groups: Adults With Sickle Cell Disease
Vaccine Hesitancy Clinical Trial 2023: Adults With Sickle Cell Disease Highlights & Side Effects. Trial Name: NCT05998824 — N/A
Adults With Sickle Cell Disease 2023 Treatment Timeline for Medical Study. Trial Name: NCT05998824 — N/A
~120 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top